Docstoc

Circulate

Document Sample
Circulate Powered By Docstoc
					                                                                                    FORCEFUL INGREDIENT INFO
General Description:

Cardiovascular disease has been the number one cause of death in the United States every year since 1900, except
1918 when influenza killed more people. Cardiovascular diseases are comprised of four main classifications:
Coronary Heart Disease (CHD), Hypertensive Disease, Rheumatic Heart Disease, and Stroke (Cerebrovascular)
Disease. In 1998 (the last year for which statistics were completed), there were 949,619 deaths due to cardiovascular
diseases. Forty-eight percent of these deaths (459,841) were due to coronary heart disease. Single-handedly, CHD is
the leading cause of American deaths, regardless of gender. It is further estimated that 12,400,000 Americans suffer
from coronary heart disease. The economic cost associated with cardiovascular disease is phenomenal, with the
direct and indirect costs for CHD in the United States estimated to be about 100.8 billion, annually.[1]

Coronary heart disease includes damage to the heart or pain in the heart because of obstructed blood flow due to
arteriosclerosis in the coronary arteries.[2] Arteriosclerosis is defined as a buildup of cholesterol and fat within the
walls of the arteries. The process can begin in childhood and worsen with age. High total cholesterol levels; high
low-density lipoprotein (LDL) cholesterol; low high-density lipoprotein (HDL) cholesterol; high rates of oxidation of
LDL (recently revealed that high oxidized LDL levels coincide with severity of acute coronary syndromes); and high
levels of homocysteine increase the risk for coronary heart disease. Other contributing factors that lead to heart
disease are high blood pressure, smoking, obesity, and physical inactivity.[2]

Policosanol: Policosanol is a natural mixture of eight relatively high molecular weight alcohols that have been
isolated and purified from sugar cane wax (Saccharum officinarum L.). Its main component is octacosanol. The other
components are triacontanol, hexacosanol, tetracosanol, heptacosanol, nonacosanol, dotriacontanol, and
tetratriacontanol. Policosanol is a cholesterol-lowering agent, with blood thinning properties. The benefits of
policosanol have been studied both in animals and in humans with few detrimental side effects being witnessed.[3, 4]

Many studies using policosanol have been performed on persons with hypercholesterolemia or hyperlipidemia, some
of the studies lasting as long as two years. A daily dose of ten milligrams of policosanol has shown on average to
reduce total cholesterols by 16.5% and LDL (“bad cholesterol”) by 24.2%, while increasing HDL (“good
cholesterol”) levels by 17%.[3, 4, 6] In other studies, policosanol has been shown to reduce platelet aggregation,[7]
lower total cholesterol and LDL,[8, 9] raise HDL,[5, 9] inhibit thromboxane, but not prostacyclin,[10] improve symptoms
of intermittent claudication[11, 12]and improve cardiovascular capacity.[13, 14] Persons with coronary heart disease
showed improvement in myocardial ischemia.[15]

When tested against other drugs, policosanol was found to be as effective at lowering total cholesterol and LDL/HDL
ratio. This ratio needs to be more balanced, especially in America where epidemiologic studies show that LDL is too
high and the HDL is too low. Policosanol was found to be better tolerated than acipimox[14] and pravastatin.[15] It
produced more preferential changes in HDL cholesterol and was better tolerated than lovastatin[16] or simvastatin.[17]
It was equally effective at reducing platelet aggregation as aspirin and some studies have found a synergistic effect
between policosanol and aspirin.[7, 18-20]

In healthy persons, policosanol reduced oxidation of LDL cholesterol[21] and reduced platelet aggregation.[20]

Policosanol is well tolerated by human subjects. Patients who took policosanol had no more adverse events than
those patients who took placebo.[3, 4] In addition, policosanol has a wide safety margin after oral administration.[22, 23]
Studies in animals found no evidence of carcinogenicity,[22, 24] toxicity,[25] or teratogenicity.[26, 27]

Although policosanol is well tolerated, there are reports that some side effects do occur, including: erythema,
migraines, insomnia, somnolence, irritability, dizziness, upset stomach, polyphagia, dysuria, weight loss, skin rash,
and nosebleeds.[28]

Oleuropein: Studies of the Mediterranean diet show that olive oil may provide protection from a variety of diseases,
including arteriosclerosis. Olive oil has been studied to determine its role as a heart protectant. One of the
components of olive oil that has been studied because of its active nature is oleuropein, a bitter phenolic compound
derived from olives.[29]
A laboratory study showed that oleuropein inhibited the oxidation of LDL cholesterol as measured by conjugated
dienes, while reducing total cholesterol by 15%, free cholesterol by 12%, and ester cholesterol by 17%.[30]

Oxidized LDL cholesterol contributes significantly to the formation of arteriosclerotic lesions and thus the severity
of symptoms associated with coronary heart disease.[31] Thus, by inhibiting this oxidation, oleuropein may also
protect against arteriosclerosis. In vitro, oleuropein protected LDL from oxidation by copper sulfate for over 6 hours
(without oleuropein the LDL was completely oxidized in 30 minutes).[32]

Oleuropein also has the added benefit of reducing blood pressure.[33, 34]

Oleuropein is considered safe in amounts that could be found in a diet high in olive oil. A diet high in olive oil
ranges from 178 mg to 312 mg a day.[32, 35-37] No side effects were reported.[38]

Folic Acid: Folic acid (pteroylmonoglutamic acid) is an essential B vitamin. Typically the average diet in the USA
does not provide enough of this essential nutrient, which often necessitates the use of a supplement.[38] The RDA for
adult males is 200µg, adult females 180µg, and pregnant females 400µg.

Epidemiological studies serve to strengthen the correlation between elevated plasma homocysteine and a higher risk
for CHD.[39, 40] Some cases of high homocysteine are not a result of nutritional deficiency; genetically some people
do not produce enough enzymes to process homocysteine. Also, kidney disease, psoriasis, medications, or low
amounts of thyroid hormone contribute to high homocysteine levels.[41] In other cases, nutritional deficiency may
increase homocysteine levels. In most of these situations, homocysteine levels can be lowered and maintained by
supplementing the diet with folic acid.[42-48] According to Malinow, a meta-analysis of 12 clinical trials shows an
estimated 25% reduction in homocysteine concentration could be achieved with folic acid supplementation, and
therefore, a reduced risk for CHD.[46]

Plasma folic acid levels have a strong inverse relationship with homocysteine levels. It has now been demonstrated
that folic acid can reduce and maintain homocysteine levels, which can help prevent some cardiovascular disease. [47,
49]



Folic acid is an essential, safe, and non-toxic vitamin in standard recommended doses. Interference with the
absorption of folic acid by the body can happen with medications such as oral contraceptives, corticosteroids,
barbiturates, phenytoin and other anti-seizure medications, sulfa drugs, some antibiotics, some anticancer drugs, and
high-dose aspirin.[50]

Vitamin B12: Vitamin B12 is a naturally occurring B complex vitamin that can be found in some foods of animal
origin. The synthetic form of vitamin B12 is known as cyanocobalamin.[51] A certain percentage of middle aged and
elderly people “mal-absorb” naturally occurring vitamin B12 and should take a supplement. Unfortunately, not all
people are able to absorb vitamin B12 from the gastro-intestinal tract due to a lack of intrinsic factor. These people
may require injected or nasally administered B12.

Vitamin B12 supports folic acid in reducing plasma homocysteine levels, making it essential to the utilization of folic
acid.[42-48] The combination of these two important vitamins facilitates proper metabolism of homocysteine.
Additionally, folic acid can mask low-grade vitamin B12 deficiency, which eventually leads to pernicious anemia and
results in irreversible nerve damage. Concurrent administration of B12 and folic acid can eliminate this possible
“masking” affect.[43] Furthermore, vitamin B12 deficiency has an impact on homocysteine concentration itself,
although the reduction is not as significant as with folic acid.[51] Another observation by Malinow demonstrates that
beside the 25% reduction of homocysteine concentrations with folic acid, an additional 7% reduction occurred with
vitamin B12 supplementation.[46] Thus a 32% reduction in homocysteine is possible by administering folic acid and
vitamin B12.

Vitamin B12 is an essential, safe, and non-toxic vitamin in standard recommended doses. There are certain
medications that can interfere with the absorption of vitamin B12 such as those that increase urinary flow, and those
that stimulate the liver. A qualified health care practitioner should evaluate possible interactions with these
medications.
__________________

         References:

1.       American Heart Association, 2001 Heart and Stroke Statistical Update. 2000, American Heart Association: Dallas,
Texas.
2.       National Heart, L., and Blood Institute, Facts about Coronary Heart Disease. 1993, NIH Publication No. 93-2265:
Bethesda, Maryland. p. 1-7.
3.       Más, R., G. Castano, J. Illnait, L. Fernandez, J. Fernandez, C. Aleman, V. Pontigas, and M. Lescay, Effects of
policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther, 1999.
65(4): p. 439-47. Center of Natural Products, National Center for Scientific Research, Havana City, Cuba.
4.       Torres, O., A.J. Agramonte, J. Illnait, R. Mas Ferreiro, L. Fernandez, and J.C. Fernandez, Treatment of
hypercholesterolemia in NIDDM with policosanol. Diabetes Care, 1995. 18(3): p. 393-7. Julio Trigo Hospital, Havana, Cuba.
5.       Canetti, M., M. Moreira, R. Mas, J. Illnait, L. Fernandez, J. Fernandez, E. Diaz, and G. Castano, A two-year study on the
efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res, 1995. 15(4): p.
159-65. "Salvador Allende" Hospital, Havana, Cuba.
6.       Pons, P., M. Rodriguez, C. Robaina, J. Illnait, R. Mas, L. Fernandez, and J.C. Fernandez, Effects of successive dose
increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J
Clin Pharmacol Res, 1994. 14(1): p. 27-33. Plaza Polyclinical Centre, Havana, Cuba.
7.       Arruzazabala, M.L., R. Mas, V. Molina, D. Carbajal, S. Mendoza, L. Fernandez, and S. Valdes, Effect of policosanol on
platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React, 1998. 20(4): p. 119-24. Center of Natural
Products, National Center for Scientific Research, Havana, Cuba.
8.       Batista, J., R. Stusser, F. Saez, and B. Perez, Effect of policosanol on hyperlipidemia and coronary heart disease in
middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther, 1996. 34(3): p. 134-7. Cardiovascular Laboratory,
Havana University, Cuba.
9.       Castaño, G., R. Mas, L. Fernandez, J.C. Fernandez, J. Illnait, L.E. Lopez, and E. Alvarez, Effects of policosanol on
postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol, 2000. 14(3): p. 187-95. Medical Surgical
Research Center (CIMEQ), Siboney, Cuba.
10.      Carbajal, D., M.L. Arruzazabala, S. Valdes, and R. Mas, Effect of policosanol on platelet aggregation and serum levels
of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids, 1998. 58(1): p. 61-4. Center of
Natural Products, CNIC, Cubanacan Habana, Cuba.
11.      Castaño, G., R. Mas Ferreiro, L. Fernandez, R. Gamez, J. Illnait, and C. Fernandez, A long-term study of policosanol in
the treatment of intermittent claudication. Angiology, 2001. 52(2): p. 115-25. Medical Surgical Research Center, Havana City
Cuba.
12.      Castaño, G., R. Mas, J. Roca, L. Fernandez, J. Illnait, J.C. Fernandez, and E. Selman, A double-blind, placebo-controlled
study of the effects of policosanol in patients with intermittent claudication. Angiology, 1999. 50(2): p. 123-30. Medical Surgical
Research Center, Havana City, Cuba.
13.      Stüsser, R., J. Batista, R. Padron, F. Sosa, and O. Pereztol, Long-term therapy with policosanol improves treadmill
exercise-ECG testing performance of coronary heart disease patients. Int J Clin Pharmacol Ther, 1998. 36(9): p. 469-73.
Clinical Research Center, Havana University, Playa, Cuba.
14.      Alcocer, L., L. Fernandez, E. Campos, and R. Mas, A comparative study of policosanol Versus acipimox in patients with
type II hypercholesterolemia. Int J Tissue React, 1999. 21(3): p. 85-92. Department of Cardiology, Mexico General Hospital,
Mexico City.
15.      Castaño, G., R. Mas, M.L. Arruzazabala, M. Noa, J. Illnait, J.C. Fernandez, V. Molina, and A. Menendez, Effects of
policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J
Clin Pharmacol Res, 1999. 19(4): p. 105-16. Medical Surgical Research Center, Havana, Cuba. dalmer@ip.etecsa.cu
16.      Crespo, N., J. Illnait, R. Mas, L. Fernandez, J. Fernandez, and G. Castano, Comparative study of the efficacy and
tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J
Clin Pharmacol Res, 1999. 19(4): p. 117-27. Enrique Cabrera Hospital, Havana, Cuba.
17.      Prat, H., O. Roman, and E. Pino, [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II
hypercholesterolemia]. Rev Med Chil, 1999. 127(3): p. 286-94. Centro Cardiovascular Hospital Clinico Universidad de Chile.
18.      Arruzazabala, M.L., S. Valdes, R. Mas, D. Carbajal, and L. Fernandez, Comparative study of policosanol, aspirin and
the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res, 1997. 36(4): p. 293-
7. Department of Pharmacology, Centre of Natural Products, CNIC, Habana, Cuba.
19.      Arruzazabala, M.L., S. Valdes, R. Mas, L. Fernandez, and D. Carbajal, Effect of policosanol successive dose increases
on platelet aggregation in healthy volunteers. Pharmacol Res, 1996. 34(5-6): p. 181-5. Departamento de Farmacologia, Centro
Nacional de Investigaciones Cientificas, Havana, Cuba.
20.      Valdes, S., M.L. Arruzazabala, L. Fernandez, R. Mas, D. Carbajal, C. Aleman, and V. Molina, Effect of policosanol on
platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res, 1996. 16(2-3): p. 67-72. Center of Natural Products,
National Center for Scientific Research, Cubanacan, Havana, Cuba.
21.      Menendez, R., R. Mas, A.M. Amor, R.M. Gonzalez, J.C. Fernandez, I. Rodeiro, M. Zayas, and S. Jimenez, Effects of
policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative
modification in vitro. Br J Clin Pharmacol, 2000. 50(3): p. 255-62. Center of Natural Products, National Center for Scientific
Research, PO Box 6880, Havana, Cuba.
22.      Aleman, C.L., R. Mas, C. Hernandez, I. Rodeiro, E. Cerejido, M. Noa, A. Capote, R. Menendez, A. Amor, V. Fraga, and
et al., A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett, 1994. 70(1): p. 77-87. Centro de
Productos Naturales, Havana City, Cuba.
23.      Gámez, R., C. Alemán, and R. Más, et.al, A 6-Month Study on the Toxicity of High Doses of Policosanol Orally
Administered to Sprague-Dawley Rats. Journal of Medicinal Food, 2001. 4((2)): p. 57-65.
24.      Aleman, C.L., R. Mas Ferreiro, M. Noa Puig, I. Rodeiro Guerra, C. Hernandez Ortega, and A. Capote, Carcinogenicity
of policosanol in Sprague Dawley rats: a 24 month study. Teratog Carcinog Mutagen, 1994. 14(5): p. 239-49. Center of Natural
Products, National Center for Scientific Research, Havana City, Cuba.
25.      Mesa, A.R., R. Mas, M. Noa, C. Hernandez, I. Rodeiro, R. Gamez, M. Garcia, A. Capote, and C.L. Aleman, Toxicity of
policosanol in beagle dogs: one-year study. Toxicol Lett, 1994. 73(2): p. 81-90. Centro de Productos Naturales, Centro Nacional
de Investigaciones Cientificas, Havana City, Cuba.
26.      Rodriguez, M.D., M. Sanchez, and H. Garcia, Multigeneration reproduction study of policosanol in rats. Toxicol Lett,
1997. 90(2-3): p. 97-106. Department of Toxicology, National Center for Scientific Research, Havana, Cuba.
27.      Rodriguez, M.D. and H. Garcia, Evaluation of peri- and post-natal toxicity of Policosanol in rats. Teratog Carcinog
Mutagen, 1998. 18(1): p. 1-7. Department of Toxicology, National Center for Scientific Research, Havana, Cuba.
28.      Database, N.M.C., Policosanol. 1995-2001, Therapeutic Research.
29.      Visioli, F. and C. Galli, Antiatherogenic components of olive oil. Curr Atheroscler Rep, 2001. 3(1): p. 64-7. Institute of
Pharmacological Sciences, University of Milan, Via Balzaretti 9, Milan 20133, Italy. francesco.visioli@unimi.it
30.      Coni, E., R. Di Benedetto, M. Di Pasquale, R. Masella, D. Modesti, R. Mattei, and E.A. Carlini, Protective effect of
oleuropein, an olive oil biophenol, on low density lipoprotein oxidizability in rabbits. Lipids, 2000. 35(1): p. 45-54. Food
Department, Istituto Superiore di Sanita, Rome, Italy. e.coni@iss.it
31.      Tsimikas, S. and J.L. Witztum, Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk.
Circulation, 2001. 103(15): p. 1930-2.
32.      Visioli, F. and C. Galli, Oleuropein protects low density lipoprotein from oxidation. Life Sci, 1994. 55(24): p. 1965-71.
University of Milan, Institute of Pharmacological Sciences, Italy.
33.      Cherif, S., N. Rahal, M. Haouala, B. Hizaoui, F. Dargouth, M. Gueddiche, Z. Kallel, G. Balansard, and K. Boukef, [A
clinical trial of a titrated Olea extract in the treatment of essential arterial hypertension]. J Pharm Belg, 1996. 51(2): p. 69-71.
Service de Cardiologie, Hopital Militaire, Tunis.
34.      Ribeiro, R., M.M. Fiuza de Melo, F. De Barros, C. Gomes, and G. Trolin, Acute antihypertensive effect in conscious rats
produced by some medicinal plants used in the state of Sao Paulo. J Ethnopharmacol, 1986. 15(3): p. 261-9.
35.      Aviram, M. and K. Eias, Dietary olive oil reduces low-density lipoprotein uptake by macrophages and decreases the
susceptibility of the lipoprotein to undergo lipid peroxidation. Ann Nutr Metab, 1993. 37(2): p. 75-84. Lipid Research
Laboratory, Rambam Medical Center, Rappaport Family Institute for Research in the Medical Sciences, Technion Faculty of
Medicine, Haifa, Israel.
36.      Aravanis, C., R.P. Mensink, N. Karalias, B. Christodoulou, A. Kafatos, and M.B. Katan, Serum lipids, apoproteins and
nutrient intake in rural Cretan boys consuming high-olive-oil diets. J Clin Epidemiol, 1988. 41(11): p. 1117-23. Medical Center
of Athens, Greece.
37.      Massaro, M., M.A. Carluccio, and R. De Caterina, Direct vascular antiatherogenic effects of oleic acid: a clue to the
cardioprotective effects of the Mediterranean diet. Cardiologia, 1999. 44(6): p. 507-13. Istituto di Fisiologia Clinica del CNR,
Pisa.
38.      Database, N.M.C., Folic Acid. 1995-2001, Therapeutic Research: Stockton, CA. p. 1-7.
39.      Graham, I.M., L.E. Daly, H.M. Refsum, K. Robinson, L.E. Brattstrom, P.M. Ueland, R.J. Palma-Reis, G.H. Boers, R.G.
Sheahan, B. Israelsson, C.S. Uiterwaal, R. Meleady, D. McMaster, P. Verhoef, J. Witteman, P. Rubba, H. Bellet, J.C. Wautrecht,
H.W. de Valk, A.C. Sales Luis, F.M. Parrot-Rouland, K.S. Tan, I. Higgins, D. Garcon, G. Andria, and et al., Plasma
homocysteine as a risk factor for vascular disease. The European Concerted Action Project. Jama, 1997. 277(22): p. 1775-81.
Department of Cardiology, Adelaide Hospital, Trinity College, Dublin, Ireland.
40.      Nygard, O., J.E. Nordrehaug, H. Refsum, P.M. Ueland, M. Farstad, and S.E. Vollset, Plasma homocysteine levels and
mortality in patients with coronary artery disease. N Engl J Med, 1997. 337(4): p. 230-6. Department of Public Health and
Primary Health Care, University of Bergen, Haukeland University Hospital, Norway.
41.      Physicians, A.A.o.F., Homocysteine. 1999. p. 1-2.
42.      Boerboom, J., V. Skarin, and X. Wu, The Role of Vitamin B-12, Vitamin B-6, and Folate in Homocysteinemia, 1-4. 1998.
43.      Boushey, C.J., S.A. Beresford, G.S. Omenn, and A.G. Motulsky, A quantitative assessment of plasma homocysteine as a
risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Jama, 1995. 274(13): p. 1049-57. Northwest
Prevention Effectiveness Center, University of Washington, Seattle 98195-7236, USA.
44.      Brouwer, I.A., M. van Dusseldorp, C.M. Thomas, M. Duran, J.G. Hautvast, T.K. Eskes, and R.P. Steegers-Theunissen,
Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am J Clin Nutr, 1999.
69(1): p. 99-104. Division of Human Nutrition and Epidemiology, Wageningen Agricultural University, Netherlands.
ingeborg.brouwer@staff.NutEpi.wau.nl
45.     Loria, C.M., D.D. Ingram, J.J. Feldman, J.D. Wright, and J.H. Madans, Serum folate and cardiovascular disease
mortality among US men and women. Arch Intern Med, 2000. 160(21): p. 3258-62. Division of Epidemiology and Clinical
Applications, National Heart, Lung, and Blood Institute, 6701 Rockledge Dr, Room 8150, Bethesda, MD 20892-7934, USA.
loriac@nih.gov
46.     Malinow, M.R., A.G. Bostom, and R.M. Krauss, Homocyst(e)ine, diet, and cardiovascular diseases: a statement for
healthcare professionals from the Nutrition Committee, American Heart Association. Circulation, 1999. 99(1): p. 178-82.
Oregon Regional Primate Research Center, Beaverton 97006-3448, USA. malinowr@ohsu.edu
47.     Selhub, J., P.F. Jacques, P.W. Wilson, D. Rush, and I.H. Rosenberg, Vitamin status and intake as primary determinants
of homocysteinemia in an elderly population. Jama, 1993. 270(22): p. 2693-8. US Department of Agriculture Human Nutrition
Research Center on Aging, Tufts University, Boston, MA 02111.
48.     Usui, M., H. Matsuoka, H. Miyazaki, S. Ueda, S. Okuda, and T. Imaizumi, Endothelial dysfunction by acute
hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Colch), 1999. 96(3): p. 235-9. Department of Internal Medicine
III, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011 Japan.
49.     Woodside, J.V., J.W. Yarnell, D. McMaster, I.S. Young, D.L. Harmon, E.E. McCrum, C.C. Patterson, K.F. Gey, A.S.
Whitehead, and A. Evans, Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind,
randomized, factorial-design, controlled trial. Am J Clin Nutr, 1998. 67(5): p. 858-66. School of Clinical Medicine, The Queen's
University of Belfast, United Kingdom. p9495754@qub.ac.uk
50.     Roberts, A.J., M.E. O'Brien, and G.J. Subak-Sharpe, Nutraceuticals : the complete encyclopedia of supplements, herbs,
vitamins, and healing foods. 2001, New York: Berkley Pub. Group. xvi, 669.
51.     Database, N.M.C., Vitamin B-12. 1995-2001, Therapeutic Research: Stockton, CA. p. 1-6.

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:1
posted:4/2/2011
language:English
pages:5